SRR934771
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 132.22733245729302
- age_years
- 44
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.197
- SPERMATOGENESIS+0.185
- MYC_TARGETS_V2+0.050
- KRAS_SIGNALING_DN+0.024
- E2F_TARGETS+0.023
- MYC_TARGETS_V1+0.016
- G2M_CHECKPOINT-0.027
- WNT_BETA_CATENIN_SIGNALING-0.082
- COAGULATION-0.086
- DNA_REPAIR-0.151
Top 10 suppressed
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.563
- HYPOXIA-0.476
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.474
- TNFA_SIGNALING_VIA_NFKB-0.454
- P53_PATHWAY-0.443
- APOPTOSIS-0.431
- MYOGENESIS-0.429
- UV_RESPONSE_DN-0.417
- ADIPOGENESIS-0.416
- ESTROGEN_RESPONSE_LATE-0.404
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934905 | — | — | 0.984 |
| 2 | SRR934972 | — | — | 0.974 |
| 3 | SRR934810 | — | — | 0.945 |
| 4 | SRR934766 | — | — | 0.944 |
| 5 | sclc265549_S73.txt | — | cohortMD1 | 0.934 |
| 6 | SRR934959 | — | — | 0.926 |
| 7 | SRR650166 | — | — | 0.922 |
| 8 | SRR934973 | — | — | 0.914 |
| 9 | BS_4W68NV3M | medulloblastoma | — | 0.912 |
| 10 | SRR26320083 | — | — | 0.912 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 6 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.197 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.185 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.050 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.024 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.023 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.016 | Inavolisib | — uncovered |